Abbisko Cayman Limited (HK:2256) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Cayman Limited has commenced a Phase II clinical trial for ABSK043, an innovative oral PD-L1 inhibitor, in combination with furmonertinib to treat advanced non-small cell lung cancer with EGFR mutations. This study aims to enhance anti-tumor efficacy, potentially marking a significant advancement in cancer treatment. Investors are advised to proceed cautiously with the company’s shares, as the success of the drug is not guaranteed.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.